Archive for the 'Liver Disease' Category
Improved Treatment For Patients With Portal Hypertension
Bleeding from ruptured esophageal varices is the main complication of portal hypertension and a major cause of death. About one-third of variceal bleeding episodes are fatal while 70% of survivors re-bleed within a year. Propranolol, the drug of choice for primary prevention of variceal bleeding, has been found to be effective in 45% of patients who have never bled, and in only 40% of patients who have had a bleeding episode before.Original post by A Hearty Life
No commentsA New Indicator For Esophageal Varix In Alcoholic Disease
Variceal hemorrhaging is associated with a high mortality rate. The early detection of esophageal varices is critical for the effective prevention of variceal hemorrhage.In daily medical practice, it is common to encounter patients with liver damage from chronic alcohol consumption. When the alcoholic patient is examined, it is often evident that alcoholic liver damage is progressing.Original post by A Hearty Life
No commentsStriving Toward Better Diagnosis And Treatment Of Liver Diseases
Researchers have made great strides in identifying the mechanisms and associations involved in liver diseases to devise better treatments. Results showing that liver cells can be created from embryonic stem cells; that innate immunity influences the response of patients to treatment for chronic hepatitis C; and a potential link between recurrent urinary tract infections and primary biliary cirrhosis (PBC); and is being presented at Digestive Disease Week® 2008 (DDW®).Original post by A Hearty Life
No commentsNew Pharmacological Effect Of Jianpi Huoxue Decoction
Professor Yi-Yang Hu and his colleagues confirmed that Jianpi Huoxue decoction (JHD) reduced the cytokine expression induced by lipopolysaccharide (LPS) and inhibited some targets in LPS-activated Kupffer cell signal pathway. This may provide new insight on the mechanism of JHD on alcoholic liver injury.Original post by A Hearty Life
No commentsNo Racial Disparities Found In Long-Term Outcomes In Recipients Of Liver Transplants
New research published in the Journal of the American College of Surgeons shows long-term survival and liver rejection rates are equivalent for African-American liver transplant patients as compared with patients of other races. The study also suggests that although other factors such as liver cancer or hepatitis may negatively influence long-term survival, race does not.Original post by Diabetes Notes
No commentsWorld Hepatitis Alliance Calls On Governments To Take Urgent Action To Tackle Chronic Viral Hepatitis B & C Epidemic
The World Hepatitis Alliance, a newly formed Non-Governmental Organisation, today called on governments around the world to do more to drive improvements in prevention, diagnosis and treatment for people living with chronic viral hepatitis B and C.Original post by Diabetes Notes
No commentsDaily Glass Of Wine Could Improve Liver Health
Researchers at UC San Diego School of Medicine are challenging conventional thinking with a study showing that modest wine consumption, defined as one glass a day, may not only be safe for the liver, but may actually decrease the prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD).Original post by Diabetes Notes
No commentsPharmasset Nominates PSI-7851 As A Lead Development Candidate For The Treatment Of Chronic Hepatitis C
Pharmasset, Inc. (Nasdaq: VRUS) has nominated PSI-7851 as a lead development candidate for the treatment of chronic hepatitis C virus (HCV). PSI-7851 is a proprietary nucleotide analogue polymerase inhibitor of HCV that is being advanced into Good Laboratory Practice (GLP) animal toxicity studies required for submission of an Investigational New Drug (IND) application with the FDA or an equivalent foreign regulatory filing.Original post by Diabetes Notes
No commentsInternational Stem Cell Corporation’s Human Parthenogenetic Stem Cells To Be Used In The Development Of Treatments For Liver Disease
International Stem Cell Corporation (OTCBB:ISCO) announced that its human parthenogenetic stem cell lines will be used in studies aimed at creating liver cells to treat human liver disease. The studies will be carried out under a Material Transfer Agreement between ISCO and the University of California, San Francisco. Holger Willenbring, MD, UCSF assistant professor of surgery, will direct the research. “The fact that Dr.Original post by Diabetes Mine
No commentsTrophos Starts Phase II Clinical Trial Of TRO19622 In Liver Disease
Trophos SA, a biopharmaceutical company specializing in the discovery and development of drugs for neurological disorders, announced today that the first patients with NonAlcoholic SteatoHepatitis (NASH) have been enrolled in an exploratory Phase IIa clinical trial of its lead product, TRO19622. It is the first study investigating the potential benefits of TRO19622 beyond neurological conditions.Original post by Diabetes Mine
No comments